Evidence map›Paper›PMID 34943432›Full record

ArticleDiagnostics (Basel, Switzerland)2021

Comparison of Two Blood-Based Genotyping Tests to Investigate the KRAS G12C Mutation in Patients with Non-Small-Cell Lung Cancer at Failure of First-Line Treatments.

Chiara Nicolazzo, Alain Gelibter, Irene Bottillo, Francesca Belardinilli, Simona Pisegna, Gianluigi De Renzi, Daniele Marinelli, Paola Grammatico, Enrico Cortesi, Giuseppe Giannini and 1 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Diagnostics (Basel, Switzerland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
0.4field-weighted citation impact, top 45% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it, 5 citations in OpenAlex.

  1. Detection ofFrontiers in oncology · 2023
    Pooled it
  2. Review
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Chiara NicolazzoCancer Liquid Biopsy Unit, Department of Molecular Medicine, Sapienza University of Rome, 00161 Rome, Italy.ORCID 0000-0002-2551-8979
Alain GelibterDepartment of Radiology, Oncology and Pathology, Sapienza University of Rome, 00161 Rome, Italy.
Irene BottilloLaboratory of Medical Genetics, Department of Molecular Medicine, Sapienza University, San Camillo-Forlanini Hospital, 00152 Rome, Italy.ORCID 0000-0003-0396-7981
Francesca BelardinilliLaboratory of Molecular Oncology, Department of Molecular Medicine, Sapienza University of Rome, 00161 Rome, Italy.
Simona PisegnaDepartment of Radiology, Oncology and Pathology, Sapienza University of Rome, 00161 Rome, Italy.
Gianluigi De RenziCancer Liquid Biopsy Unit, Department of Molecular Medicine, Sapienza University of Rome, 00161 Rome, Italy.
Daniele MarinelliDepartment of Radiology, Oncology and Pathology, Sapienza University of Rome, 00161 Rome, Italy.
Paola GrammaticoLaboratory of Medical Genetics, Department of Molecular Medicine, Sapienza University, San Camillo-Forlanini Hospital, 00152 Rome, Italy.
Enrico CortesiDepartment of Radiology, Oncology and Pathology, Sapienza University of Rome, 00161 Rome, Italy.
Giuseppe GianniniLaboratory of Molecular Oncology, Department of Molecular Medicine, Sapienza University of Rome, 00161 Rome, Italy.ORCID 0000-0003-0299-4056
Paola GazzanigaCancer Liquid Biopsy Unit, Department of Molecular Medicine, Sapienza University of Rome, 00161 Rome, Italy.ORCID 0000-0002-2325-2273
Sapienza University of Rome · ITCarlo Forlanini Hospital · IT

Funding

Sapienza University of Rome RG11715C7D8D18DB (P.Gr.)Sapienza University of Rome RM11916B31436754 (P.Ga.)
6 · The paper itself

Abstract

Although molecular profiling at diagnosis has traditionally relied on direct sampling of neoplastic tissue, cancer clonal evolution represents a critical obstacle to use primary tissue biopsies to guide clinical decision-making at the time of progressive disease. Liquid biopsies might offer enormous advantages over tissue biopsies, tracking in real-time temporal-based tumor dynamics following each line of treatment. Here, we compared two liquid biopsy assays, specifically real-time polymerase chain reaction and next-generation sequencing, to track the KRAS G12C mutation at onset of progression from previous lines of therapy. The KRAS G12C mutation was acquired at the time of progressive disease in 24% of patients. Furthermore, all patients with KRAS G12C mutation-positive tissue became negative in ctDNA at progressive disease. The presence of other somatic mutations in all these samples confirmed the tumor origin of the circulating DNA. This pilot study suggests that in the assessment of the plasma KRAS G12C mutation as a druggable target, real-time PCR assay Idylla might be a suitable approach to better match patients to interventional biomarker-targeted therapies.

Indexed as

circulating tumor DNAclonal evolutionKRAS G12Cliquid biopsynon-small-cell lung cancer

Identifiers

PMID34943432
PMCPMC8700393
OpenAlexW3217727457

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.